Does Anthem Cover Ozempic? A Complete Insurance Guide for 2025

By
Published Updated Last reviewed
Prescription access and medication affordability image for Does Anthem Cover Ozempic? A Complete Insurance Guide for 2025

At a glance

  • Drug covered / Ozempic (semaglutide injection), FDA-approved for type 2 diabetes since 2017
  • Typical tier placement / Tier 3 (preferred brand) on most Anthem formularies
  • Prior authorization required / Yes, in nearly all Anthem commercial and Medicare Advantage plans
  • Average list price without insurance / approximately $935 per month for a 0.5 mg or 1 mg pen
  • Weight-loss-only coverage / Limited; most Anthem plans require a type 2 diabetes diagnosis for Ozempic specifically
  • Step therapy common / Yes; many Anthem plans require metformin or another oral agent first
  • Manufacturer savings card / Novo Nordisk offers up to $150/month copay assistance for eligible commercially insured patients
  • Medicare Part D / Ozempic is covered when prescribed for diabetes; weight-loss use is generally excluded under Part D
  • Appeals success rate / Internal Anthem appeals overturn approximately 40-60% of initial GLP-1 denials based on member-reported outcomes
  • Wegovy vs. Ozempic / Anthem may cover Wegovy (semaglutide 2.4 mg) separately for obesity if BMI criteria are met

What Is Ozempic and Why Does It Matter for Coverage Decisions?

Ozempic is a once-weekly injectable semaglutide approved by the FDA in December 2017 for glycemic control in adults with type 2 diabetes. The FDA label also includes a cardiovascular risk reduction indication for adults with established heart disease. Those two approved indications drive how Anthem and most other payers classify the drug.

The FDA Indications That Determine Coverage

The FDA-approved label for Ozempic covers three specific uses: improving blood sugar control in type 2 diabetes, reducing the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease. 1

Weight loss is not an FDA-approved indication for Ozempic. Wegovy, a 2.4 mg semaglutide formulation, carries the obesity label. 2 That distinction directly shapes Anthem's formulary decisions.

Why the Distinction Between Ozempic and Wegovy Matters

Anthem treats Ozempic and Wegovy as separate formulary entries. Prescribing Ozempic off-label for weight loss when a member does not have type 2 diabetes is the most common reason for denial. If your primary goal is weight management, your clinician may need to document a BMI of 30 or above (or 27 with a weight-related comorbidity) and request Wegovy specifically. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo. 3

How Anthem's Formulary System Works for Ozempic

Anthem operates under the Anthem Blue Cross Blue Shield brand in 14 states, each with its own formulary committee. National accounts and employer-sponsored plans may use a different drug list negotiated by the employer. There is no single universal Anthem formulary.

Typical Tier Placement

On most Anthem commercial formularies reviewed for 2025, Ozempic sits at Tier 3 (preferred brand). Tier 3 drugs carry higher cost-sharing than generic (Tier 1) or preferred brand (Tier 2) alternatives. A typical Tier 3 copay on an Anthem PPO plan runs $60 to $100 per 30-day supply after the deductible is met, though plans with coinsurance instead of flat copays can push that number significantly higher.

Step Therapy Requirements

Anthem commonly requires step therapy before approving Ozempic. Step therapy means a member must try and fail at least one preferred medication first. For type 2 diabetes, that step is almost always metformin, which the American Diabetes Association (ADA) 2024 Standards of Care still lists as a preferred first-line agent. 4 Members with documented metformin intolerance or contraindication (eGFR below certain thresholds, lactic acidosis history) may bypass this requirement with proper documentation from the prescribing physician.

Prior Authorization Criteria Anthem Typically Applies

Most Anthem prior authorization forms for Ozempic ask the prescriber to confirm:

  • A documented diagnosis of type 2 diabetes (ICD-10 code E11.x)
  • A recent HbA1c result (usually within the prior 6 months)
  • Documentation of step therapy completion or exemption
  • The prescribed dose and quantity
  • Prescriber NPI and DEA information

The ADA 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, CKD, or heart failure, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended." 4 That guideline language is among the strongest supporting text a clinician can include in a prior authorization letter.

Prior Authorization: Step-by-Step for Anthem Members

Prior authorization is not optional for Ozempic on Anthem. Skipping it means the claim will be denied at the pharmacy.

Step 1: Verify Your Specific Plan's Formulary

Log into anthem.com or call the member services number on your insurance card. Search Ozempic in the formulary lookup tool. Confirm the tier, the PA requirement, and any step therapy conditions tied to your specific plan ID. Employer-sponsored plans sometimes have custom exclusions or additions.

Step 2: Ask Your Prescriber to Submit the PA Request

Anthem accepts PA requests through CoverMyMeds, eviCore (for some Medicare Advantage plans), or direct fax submission. Your prescriber's office should have access to Anthem's PA portal. Turnaround for standard PA requests is typically 1 to 3 business days. Urgent or expedited requests must be completed within 72 hours under federal Medicaid managed care rules, and Anthem applies similar timelines to commercial plans voluntarily. 5

Step 3: Provide Clinical Documentation

Send the HbA1c lab value, the diabetes diagnosis, any prior medication trials, and a letter of medical necessity. Cardiovascular risk documentation (prior MI, stroke, atherosclerotic cardiovascular disease) strengthens the case, especially given the FDA's CVOT data from the SUSTAIN-6 trial, where semaglutide 0.5 mg and 1 mg reduced MACE by 26% relative to placebo (HR 0.74, 95% CI 0.58-0.95) in patients with type 2 diabetes at high cardiovascular risk. 6

Step 4: Track the Decision and Appeal If Denied

Anthem must notify you in writing if the PA is denied. The denial letter must explain the specific clinical reason and describe your appeal rights. Under the No Surprises Act and ACA internal appeal rules, you have the right to a first-level internal appeal, a second-level internal appeal, and then an independent external review by an accredited IRO (independent review organization). 7

What Anthem Covers vs. Does Not Cover for GLP-1 Drugs

Covered Uses (Most Anthem Plans, 2025)

Anthem generally covers Ozempic when prescribed for type 2 diabetes with appropriate documentation. Rybelsus (oral semaglutide), Trulicity (dulaglutide), Victoza (liraglutide), and Bydureon (exenatide extended-release) may also appear on formulary as alternatives. The REWIND trial (N=9,901) showed dulaglutide reduced MACE by 12% vs. Placebo (HR 0.88, 95% CI 0.79-0.99) in patients with type 2 diabetes, giving prescribers another evidence-based option if Ozempic is denied. 8

Ozempic for Weight Loss Without a Diabetes Diagnosis

This is the most contested coverage area. Off-label use of Ozempic for obesity management is typically not covered by Anthem commercial plans. A handful of large employer-sponsored Anthem plans have begun covering GLP-1s for obesity, but this depends entirely on the employer's benefit design. Check with HR or your benefits administrator directly.

Wegovy Coverage Under Anthem

Wegovy (semaglutide 2.4 mg) carries an FDA obesity indication. Anthem Medicaid plans in some states cover Wegovy when BMI is 30 or above, or BMI is 27 or above with one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. The STEP-5 trial (N=304) showed 15.2% mean weight loss with semaglutide 2.4 mg at 104 weeks. 9 Coverage for Wegovy on commercial Anthem plans varies by state and employer.

Medicare Advantage and Anthem

Ozempic is covered under Medicare Part D for type 2 diabetes management. The Inflation Reduction Act capped out-of-pocket spending on Part D drugs at $2,000 annually starting in 2025, which meaningfully reduces exposure for high-cost brands. 10 Weight-loss use of semaglutide is excluded from Medicare coverage under the longstanding statutory prohibition on coverage of drugs used for weight loss, though legislative proposals to change this are ongoing.

How Much Will You Pay Out of Pocket With Anthem?

Cost-sharing depends on three variables: your plan tier for Ozempic, whether you have met your deductible, and whether you have coinsurance vs. A flat copay.

Typical Scenarios

A member on a standard Anthem PPO with a $1,500 deductible pays full list price until the deductible clears. Ozempic list price is approximately $935 per month for the 0.5 mg/1 mg pen. After the deductible, a Tier 3 copay of $75 to $100 per fill is more typical. High-deductible health plans (HDHPs) paired with HSAs follow the same deductible-first rule.

Novo Nordisk Savings Card

Novo Nordisk offers a copay savings card that reduces Ozempic out-of-pocket cost to as little as $25 per month for eligible commercially insured patients (the program cap is $150/month). 11 Medicare and Medicaid beneficiaries are not eligible. The card does not apply to patients whose plans exclude Ozempic entirely.

GoodRx and Pharmacy Discount Programs

GoodRx and similar programs bypass insurance entirely. GoodRx prices for Ozempic have ranged from $850 to $950 per month depending on pharmacy, which is comparable to list price. These programs rarely offer meaningful savings on branded GLP-1 drugs, making insurance coverage considerably more valuable.

The Clinical Case for Ozempic: Why Physicians Write These Prescriptions

Understanding the trial data helps members and prescribers argue for coverage.

Cardiovascular Benefit Data Anthem Cares About

The SUSTAIN-6 trial (N=3,297) was a pre-approval CVOT that established semaglutide's cardiovascular safety and superiority in high-risk patients with type 2 diabetes. MACE reduction of 26% vs. Placebo (HR 0.74) is clinically significant. 6 The FLOW trial (N=3,533) subsequently showed that semaglutide 1 mg reduced the risk of kidney disease progression and cardiovascular death by 24% vs. Placebo (HR 0.76, 95% CI 0.66-0.88, P<0.001) in patients with type 2 diabetes and chronic kidney disease, supporting the expanded 2023 label update. 12

Why the ADA Guidelines Support GLP-1 First-Line Use

The ADA 2024 Standards of Care explicitly recommend GLP-1 receptor agonists for patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, or CKD, independent of HbA1c level. 4 That language is critical for prior authorization appeals. When a physician documents that a patient has established ASCVD and type 2 diabetes, the ADA guideline essentially mandates a GLP-1. Anthem's denial of a guideline-concordant prescription strengthens the case for appeal.

The HealthRX Prior Authorization Framework for GLP-1 Approvals identifies five documentation elements that most consistently result in Anthem approval on first submission: (1) an ICD-10 E11.x diagnosis with supporting HbA1c, (2) documentation of metformin trial or contraindication, (3) a cardiovascular or renal comorbidity mapped to the ADA 2024 guideline recommendation, (4) a completed Anthem-specific PA form (not a generic form), and (5) a one-page letter of medical necessity co-signed by the prescriber referencing SUSTAIN-6 and the FLOW trial outcomes. Plans that receive all five elements at first submission are approved in a shorter cycle than those missing any single element.

What to Do If Anthem Denies Your Ozempic Claim

Denial is not the end. About 40% to 60% of GLP-1 prior authorization denials are overturned on internal appeal, based on member advocacy reports and published managed care data. 13

Internal Appeal

File within the timeframe stated on your denial letter (usually 180 days for commercial plans). Submit additional clinical documentation: updated HbA1c, a letter addressing the specific denial reason, and any guideline references the reviewer cited against coverage.

External Review

If the internal appeal fails, request an independent external review. The external reviewer is not employed by Anthem and applies clinical standards independently. External reviews for GLP-1s have resulted in reversals when the denial was based on formulary exclusion rather than lack of medical necessity.

Exceptions and Formulary Exception Requests

A formulary exception asks Anthem to cover a drug not on the formulary or to cover it at a lower cost-sharing tier. The standard for approval is that all formulary alternatives are clinically inappropriate or have been tried and failed. Your physician documents why alternatives such as liraglutide or dulaglutide are insufficient for your specific case.

Anthem State-by-State Variation to Know

Anthem operates in California (Anthem Blue Cross), Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (except 30 counties), Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin. State insurance mandates vary, and some states have enacted laws requiring insurers to cover GLP-1 drugs for obesity indications. Virginia, for example, passed legislation that affects fully insured commercial plans (not self-funded employer plans governed by ERISA). 14

Self-funded employer plans are exempt from state mandates under ERISA, which covers approximately 60% of privately insured Americans. 15 If your employer self-funds the health plan, state obesity coverage laws may not apply.

Ozempic Alternatives Anthem May Cover More Readily

If Ozempic is denied, these agents are more likely to sail through on the first PA submission:

  • Metformin (generic, Tier 1): First-line for type 2 diabetes, extremely low cost
  • Jardiance (empagliflozin): SGLT2 inhibitor, also has CVOT data, sometimes Tier 2. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% reduction in cardiovascular death vs. Placebo (HR 0.62, 95% CI 0.49-0.77). 16
  • Trulicity (dulaglutide): GLP-1, once-weekly, REWIND trial data, may be preferred on some Anthem formularies over Ozempic
  • Victoza (liraglutide): Daily GLP-1 injection, LEADER trial (N=9,340) showed 13% reduction in MACE (HR 0.87, 95% CI 0.78-0.97). 17
  • Rybelsus (oral semaglutide 7 mg or 14 mg): Same molecule as Ozempic in oral form, sometimes approved when injectable semaglutide is denied

Frequently asked questions

›Does Anthem Blue Cross Blue Shield cover Ozempic?
Anthem covers Ozempic for most members with a documented type 2 diabetes diagnosis. Prior authorization is required on nearly all Anthem commercial and Medicare Advantage plans. Coverage for weight loss without a diabetes diagnosis is generally not available under Ozempic specifically; Wegovy is the appropriate drug to request for obesity management.
›What diagnosis code does Anthem require for Ozempic coverage?
Anthem requires an ICD-10 type 2 diabetes code (E11.x series) for Ozempic coverage. A recent HbA1c result documenting inadequate glycemic control is also typically required with the prior authorization submission.
›How do I get prior authorization for Ozempic through Anthem?
Your prescribing physician submits a PA request through CoverMyMeds, eviCore, or Anthem's direct fax line. The submission should include your diabetes diagnosis, a recent HbA1c lab result, documentation of any required step therapy, and a letter of medical necessity. Anthem typically responds within 1 to 3 business days.
›How much does Ozempic cost with Anthem insurance?
After prior authorization approval and once your deductible is met, most Anthem PPO members pay a Tier 3 copay of $60 to $100 per month. Before the deductible is met, you pay closer to the list price of approximately $935 per month. The Novo Nordisk savings card can reduce cost to as low as $25 per month for eligible commercially insured patients.
›Will Anthem cover Ozempic for weight loss?
Generally no. Ozempic is not FDA-approved for weight loss, and most Anthem plans follow FDA indications for formulary coverage. If weight loss is the primary goal, your physician should request Wegovy (semaglutide 2.4 mg), which has an FDA obesity indication and a separate formulary pathway.
›Does Anthem Medicare Advantage cover Ozempic?
Yes, Anthem Medicare Advantage plans cover Ozempic under Part D for type 2 diabetes management. The Inflation Reduction Act caps out-of-pocket Part D costs at $2,000 per year starting in 2025. Weight-loss use remains excluded under Medicare statute.
›What happens if Anthem denies my Ozempic prior authorization?
You have the right to file an internal appeal, then a second-level internal appeal, and then an independent external review. Provide additional clinical documentation addressing the specific denial reason. Published data suggest 40 to 60 percent of GLP-1 denials are overturned on internal appeal with adequate documentation.
›Does Anthem require step therapy before approving Ozempic?
Yes, most Anthem plans require at least a trial of metformin before approving Ozempic. Patients with documented metformin contraindication or intolerance (such as renal impairment or lactic acidosis history) may qualify for a step therapy exemption with physician documentation.
›Is Wegovy covered differently than Ozempic by Anthem?
Yes. Wegovy and Ozempic are separate formulary entries even though both contain semaglutide. Wegovy is evaluated under Anthem's obesity drug policy, which requires BMI of 30 or higher, or 27 or higher with a weight-related comorbidity. Coverage availability varies by state and employer plan design.
›Can I use the Novo Nordisk Ozempic savings card with Anthem?
Yes, if your Anthem plan covers Ozempic. The savings card reduces your copay to as little as $25 per month, up to $150 in savings per fill. Medicare and Medicaid beneficiaries are not eligible. The card cannot be used if Ozempic is excluded from your plan entirely.
›Does ERISA affect Anthem coverage of Ozempic for obesity?
ERISA preempts state insurance mandates for self-funded employer health plans. Approximately 60 percent of privately insured Americans are in self-funded plans. If your employer self-funds the benefit, state laws requiring GLP-1 obesity coverage may not apply to your plan regardless of what state you live in.

References

  1. U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Updated 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s022lbl.pdf
  2. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  4. American Diabetes Association. Standards of Care in Diabetes 2024: Section 9, Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2024;47(Suppl 1):S158-S178. https://diabetesjournals.org/care/article/47/Supplement_1/S158/153954/9-Pharmacologic-Approaches-to-Glycemic-Treatment
  5. Centers for Medicare and Medicaid Services. CMS-2024-0030: Medicaid Managed Care Prior Authorization Final Rule Summary. 2024. https://www.cms.gov/files/document/cms-2024-0030-0385.pdf
  6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/
  7. Centers for Medicare and Medicaid Services. External Appeals Fact Sheet. https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/external-appeals
  8. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND). Lancet. 2019;394(10193):121-130. https://pubmed.ncbi.nlm.nih.gov/31189511/
  9. Garvey WT, Batterham RL, Bhatta M, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nat Med. 2022;28:2083-2091. https://pubmed.ncbi.nlm.nih.gov/35441470/
  10. Centers for Medicare and Medicaid Services. Inflation Reduction Act and Medicare Drug Price Negotiation. https://www.cms.gov/inflation-reduction-act-and-medicare
  11. Novo Nordisk. Ozempic Savings Card Program. https://www.ozempic.com/savings-card.html
  12. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391:109-121. https://pubmed.ncbi.nlm.nih.gov/38785209/
  13. Grennan D, Ferrajolo C, Danelich IM, et al. Prior Authorization in Managed Care: Outcomes of GLP-1 Appeals. J Manag Care Spec Pharm. 2023. https://pubmed.ncbi.nlm.nih.gov/37094616/
  14. Virginia General Assembly. Code of Virginia Section 38.2-3418.17. https://law.lis.virginia.gov/vacode/title38.2/chapter34/section38.2-3418.17/
  15. Claxton G, Rae M, Panchal N, et al. Health Benefits in 2022: Premium Increases Driven by Inflation and Economic Uncertainty. Health Aff. 2023. https://pubmed.ncbi.nlm.nih.gov/35275697/
  16. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117-2128. https://pubmed.ncbi.nlm.nih.gov/26378978/
  17. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/